|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirsch FR, Varella-Garcia M, Bunn PA Jr,
Di Maria MV, Veve R, Bremmes RM, Barón AE, Zeng C and Franklin WA:
Epidermal growth factor receptor in non-small-cell lung carcinomas:
Correlation between gene copy number and protein expression and
impact on prognosis. J Clin Oncol. 21:3798–3807. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M, Popat S, Reinmuth N, de Ruysscher
D, Kerr KM and Peters S; ESMO Guidelines Working Group: Metastatic
non-small-cell lung cancer (NSCLC): ESMO Clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol.
25(Suppl 3): iii27–iii39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vallières E, Shepherd FA, Crowley J, van
Houtte P, Postmus PE, Carney D, Chansky K, Shaikh Z and Goldstraw
P: International Association for the Study of Lung Cancer
International Staging Committee and Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals regarding the
relevance of TNM in the pathologic staging of small cell lung
cancer in the forthcoming (seventh) edition of the TNM
classification for lung cancer. J Thorac. 4:1049–1059. 2009.
View Article : Google Scholar
|
|
5
|
Flens MJ, Zaman GJ, van der Valk P,
Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas
M, Meijer CJ and Scheper RJ: Tissue distribution of the multidrug
resistance protein. Am J Pathol. 148:1237–1247. 1996.PubMed/NCBI
|
|
6
|
Schinkel AH and Jonker JW: Mammalian drug
efflux transporters of the ATP binding cassette (ABC) family: An
overview. Adv Drug Deliv Rev. 55:3–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cole SP: Targeting multidrug resistance
protein 1 (MRP1, ABCC1): Past, present, and future. Ann Rev
Pharmacol Toxicol. 54:95–117. 2014. View Article : Google Scholar
|
|
8
|
Li A, Song J, Lai Q, Liu B, Wang H, Xu Y,
Feng X, Sun X and Du Z: Hypermethylation of ATP-binding cassette B1
(ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin
resistance in the A549 lung adenocarcinoma cell line. Int J Exp
Pathol. 97:412–421. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen JJ, Liu SP, Zhao J, Wang SC, Liu TJ
and Li X: Effects of a novel photoactivated photosensitizer on MDR1
over-expressing human breast cancer cells. J Photochem Photobiol B
Biol. 171:67–74. 2017. View Article : Google Scholar
|
|
10
|
Melguizo C, Prados J, Luque R, Ortiz R,
Caba O, Alvarez PJ, Gonzalez B and Aranega A: Modulation of MDR1
and MRP3 gene expression in lung cancer cells after paclitaxel and
carboplatin exposure. Int J Mol Sci. 13:16624–16635. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luque R, Gonzalez Flores E, Delgado JR,
Melguizo C, Prados JC, Gonzalez Astorga B, Ortiz R, Sánchez Toro C,
Valdivia J and Aránega A: MDR1 gene expression in peripheral blood
as a marker of treatment response in lung cancer. J Clin Oncol.
30:962012. View Article : Google Scholar
|
|
12
|
Wu DD, Zhang JX, Li J and Dong WG: Lack of
association of the MDR1 C3435T polymorphism with susceptibility to
gastric cancer and peptic ulcer: A systemic review and
meta-analysis. Asian Pac J Cancer Prev. 15:3021–3027. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiao W, Wang T, Zhang L, Tang Q, Wang D
and Sun H: Association between single genetic polymorphisms of MDR1
gene and gastric cancer susceptibility in Chinese. Med Oncol.
30:6432013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bambace NM and Holmes CE: The platelet
contribution to cancer progression. J Thromb Haemost. 9:237–249.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Goubran HA, Stakiw J, Radosevic M and
Burnouf T: Platelet-cancer interactions. Semin Thromb Hemost.
40:296–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li FX, Wei LJ, Zhang H, Li SX and Liu JT:
Significance of thrombocytosis in clinicopathologic characteristics
and prognosis of gastric cancer. Asian Pac J Cancer Prev.
15:6511–6517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chadha AS, Kocak-Uzel E, Das P, Minsky BD,
Delclos ME, Mahmood U, Guha S, Ahmad M, Varadhachary GR and Javle
M: et alParaneoplastic thrombocytosis independently predicts
poor prognosis in patients with locally advanced pancreatic cancer.
Acta Oncol. 54:971–978. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng Z, Wen H, Bi R, Duan Y, Yang W and Wu
X: Thrombocytosis and hyperfibrinogenemia are predictive factors of
clinical outcomes in high-grade serous ovarian cancer patients. BMC
Cancer. 16:432016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Josa V, Krzystanek M, Eklund AC, Salamon
F, Zarand A, Szallasi Z and Baranyai Z: Relationship of
postoperative thrombocytosis and survival of patients with
colorectal cancer. Int J Surg. 18:1–6. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Taucher S, Salat A, Gnant M, Kwasny W,
Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M and Tausch
C: et alImpact of pretreatment thrombocytosis on survival in
primary breast cancer. Thromb Haemost. 89:1098–1106. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ
and van Schil PE: et alInternational association for the
study of lung cancer/american thoracic society/european respiratory
society international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berger W, Elbling L, Hauptmann E and
Micksche M: Expression of the multidrug resistanceassociated
protein (MRP) and chemoresistance of human non-small-cell lung
cancer cells. Int J Cancer 1997:. 73:84–93. 1997.
|
|
23
|
Young LC, Campling BG, Voskoglou-Nomikos
T, Cole SP, Deeley RG and Gerlach JH: Expression of multidrug
resistance protein-related genes in lung cancer: Correlation with
drug response. Clin Cancer Res. 5:673–680. 1999.PubMed/NCBI
|
|
24
|
Young LC, Campling BG, Cole SP, Deeley RG
and Gerlach JH: Multidrug resistance proteins MRP3, MRP1, and MRP2
in lung cancer: Correlation of protein levels with drug response
and messenger RNA levels. Clin Cancer Res. 7:1798–1804.
2001.PubMed/NCBI
|
|
25
|
Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki
M, Inoue H, Yamazaki H, Ueyama Y, Takagi K and Ogata T: et
alExpression of the multidrug resistance-associated protein
(MRP) gene in non-small-cell lung cancer. Br J Cancer. 72:550–554.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oshika Y, Nakamura M, Tokunaga T,
Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N and Ueyama Y:
Multidrug resistance-associated protein and mutant p53 protein
expression in non-small cell lung cancer. Mod Pathol. 11:1059–1063.
1998.PubMed/NCBI
|
|
27
|
Berger W, Setinek U, Hollaus P, Zidek T,
Steiner E, Elbling L, Cantonati H, Attems J, Gsur A and Micksche M:
Multidrug resistance markers P-glycoprotein, multidrug resistance
protein 1, and lung resistance protein in non-small cell lung
cancer: Prognostic implications. J Cancer Res Clin Oncol.
131:355–363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoh K, Ishii G, Yokose T, Minegishi Y,
Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M and Ochiai A: Breast
cancer resistance protein impacts clinical outcome in
platinum-based chemotherapy for advanced non-small cell lung
cancer. Clin Cancer Res. 10:1691–1697. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Filipits M, Haddad V, Schmid K, Huynh A,
Dunant A, André F, Brambilla E, Stahel R, Pignon JP and Soria JC:
et alMultidrug resistance proteins do not predict benefit of
adjuvant chemotherapy in patients with completely resected
non-small cell lung cancer: International Adjuvant Lung Cancer
Trial Biologic Program. Clin Cancer Res. 13:3892–3898. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dvorak HF, Brown LF, Detmar M and Dvorak
AM: Vascular permeability factor/vascular endothelial growth
factor, microvascular hyperpermeability, and angiogenesis. Am J
Pathol. 146:1029–1039. 1995.PubMed/NCBI
|
|
31
|
Ma L, Perini R, McKnight W, Dicay M, Klein
A, Hollenberg MD and Wallace JL: Proteinase-activated receptors 1
and 4 counter-regulate endostatin and VEGF release from human
platelets. Proc Natl Acad Sci USA. 102:216–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lewalle JM, Castronovo V, Goffinet G and
Foidart JM: Malignant cell attachment to endothelium of ex vivo
perfused human umbilical vein. Modulation by platelets, plasma and
fibronectin. Thromb Res. 62:287–298. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shim M, Song C, Park S, Choi SK, Cho YM,
Kim CS and Ahn H: Prognostic significance of platelet-derived
growth factor receptor-β expression in localized clear cell renal
cell carcinoma. J Cancer Res Clin Oncol. 141:2213–2220. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jurasz P, Alonso-Escolano D and Radomski
MW: Platelet-cancer interactions: Mechanisms and pharmacology of
tumour cell-induced platelet aggregation. Br J Pharmacol.
143:819–826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bobek V and Kovarík J: Antitumor and
antimetastatic effect of warfarin and heparins. Biomed
Pharmacother. 58:213–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blom JW, Osanto S and Rosendaal FR: The
risk of a venous thrombotic event in lung cancer patients: Higher
risk for adenocarcinoma than squamous cell carcinoma. J Thromb
Haemost. 2:1760–1765. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Barcala JG, Portal JA, Carmona MJ and
González CM: Exposure to environmental contaminants and respiratory
disease. Spotlight on the year 2009. Arch Bronconeumol. 46(Suppl
1): S17–S20. 2010.(In Spanish).
|
